- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.12. | TScan Therapeutics, Inc.: TScan Therapeutics Announces Positive Updated Data from the ALLOHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition | 42 | GlobeNewswire (Europe) | Treatment arm continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23) and overall survival (HR=0.61; p=0.52) 3/3 (100%) of TSC-101-treated patients who reached two-year follow-up... ► Artikel lesen | |
| 04.12. | TScan Therapeutics To Provide Update On Phase 1 Trial Of TSC-101 In Heme Malignancies Next Week | 1 | RTTNews | ||
| 03.12. | TScan Therapeutics lädt zu KOL-Event über aktualisierte ALLOHA-Studiendaten | 1 | Investing.com Deutsch | ||
| 03.12. | TScan Therapeutics, Inc.: TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA Phase 1 Trial and Future Market Opportunities | 2 | GlobeNewswire (USA) | ||
| 26.11. | TScan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| TSCAN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 14.11. | Morgan Stanley downgrades Tscan Therapeutics stock on delayed trials | 6 | Investing.com | ||
| 12.11. | Tscan Therapeutics: EPS übertrifft Schätzungen um 0,06 $ - Umsatz besser als erwartet | 1 | Investing.com Deutsch | ||
| 12.11. | TScan Therapeutics, Inc. Q3 Loss Increases, But Beats Estimates | - | RTTNews | ||
| 12.11. | TScan Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 12.11. | TScan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 04.11. | BTIG downgrades Tscan Therapeutics stock to Neutral on program delays | 3 | Investing.com | ||
| 03.11. | Tscan Therapeutics-Aktie bricht nach Aussetzung einer Studie zu soliden Tumoren ein | 6 | Investing.com Deutsch | ||
| 03.11. | TScan lays off 30% of workforce, halts phase 1 solid tumor T-cell receptor trial | 2 | FierceBiotech | ||
| 03.11. | TScan to focus on heme program, cuts workforce by 30% amid FDA progress | 5 | Investing.com | ||
| 03.11. | TScan Therapeutics, Inc.: TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027 | 279 | GlobeNewswire (Europe) | Positive end of Phase I meeting and agreement reached with FDA on pivotal study design for TSC-101 Dosed first solid tumor patients with multiplex TCR-T therapy; paused further enrollment to prioritize... ► Artikel lesen | |
| 03.11. | TScan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 17.09. | TScan Therapeutics, Inc.: TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025 | 2 | GlobeNewswire (USA) | ||
| 09.09. | TScan Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.08. | TScan Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.08. | Tscan Therapeutics: EPS übertrifft Schätzungen um 0,05 $ - Umsatz besser als erwartet | 4 | Investing.com Deutsch |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 80,85 | +0,06 % | BioNTech SE: Erste Ergebnisse aus BioNTechs und BMS' globaler Phase-2-Studie mit bispezifischem PD-L1xVEGF-A-Antikörperkandidat Pumitamig zeigten ermutigende Anti-Tumor-Aktivität bei fortgeschrittenem dreifach negativem Brustkrebs | Zwischenergebnisse der globalen klinischen Phase-2-Studie bei lokal fortgeschrittenem/metastasiertem dreifach negativem Brustkrebs (triple-negative breast cancer, "TNBC") zeigten eine ermutigende Anti-Tumor-Aktivität... ► Artikel lesen | |
| MEDIGENE | 0,025 | -6,02 % | MEDIGENE AG stürzt ab - ich traue meinen Augen nicht! | ||
| AMGEN | 268,60 | -0,79 % | FDA Greenlights Amgen's UPLIZNA For Adults With Generalised Myasthenia Gravis | THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN), Friday, announced that the FDA has expanded UPLIZNA's label to include the treatment of generalized myasthenia gravis in adults who are positive... ► Artikel lesen | |
| BIOGEN | 148,20 | -0,10 % | Lululemon, Biogen to exit Nasdaq 100 with Alnylam, Seagate among additions | ||
| BIOFRONTERA | 2,580 | -3,73 % | BIOFRONTERA AG: Jetzt kippt das Gleichgewicht! | ||
| CORE ONE LABS | 0,079 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.09.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 22.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.09.2025ISIN NameAU000000PEK2 PEAK... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 625,40 | -0,98 % | Regeneron Reports Promising Phase 1/2 Data Of Lynozyfic In Newly Diagnosed Multiple Myeloma | WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals Inc. (REGN) announced encouraging results from the Phase 1/2 LINKER-MM4 trial evaluating Lynozyfic (linvoseltamab) in adults with newly diagnosed... ► Artikel lesen | |
| EDITAS MEDICINE | 2,100 | -2,78 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| GALAPAGOS NV | 27,120 | -1,60 % | Galapagos NV: Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 2025 | High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell therapy... ► Artikel lesen | |
| IMMATICS | 8,510 | -0,58 % | Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress | IMA203CD8 is a second-generation PRAME cell therapy with enhanced pharmacology in ongoing Phase 1a dose escalationManageable tolerability across all dose levelsEncouraging early clinical anti-tumor... ► Artikel lesen | |
| AUTOLUS THERAPEUTICS | 1,380 | 0,00 % | Autolus Reveals Latest Phase I Findings For Obe-cel In Hard-to-Treat Lupus | ||
| IGM BIOSCIENCES | 1,080 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 14.08.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 14.08.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 14.08.2025.ISIN NameCA87168M1068 SYNEX... ► Artikel lesen | |
| ONCOPEPTIDES | 0,451 | -7,58 % | Oncopeptides AB: Oncopeptides publishes Q3 report 2025 | Stockholm - November 5, 2025 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today publishes the report for the third quarter 2025.
"The third... ► Artikel lesen | |
| AVACTA | 0,860 | +1,18 % | IN BRIEF: Avacta to announce initial phase 1b data on faridoxorubicin | ||
| DERMATA THERAPEUTICS | 2,630 | -4,36 % | Dermata Therapeutics: A New Realm of Skincare is Coming: Dermata Teases New OTC Brand Identity | SAN DIEGO, CA / ACCESS Newswire / December 4, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced... ► Artikel lesen |
Das Unternehmen TSCAN THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,015 Euro und damit -5,14 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TSCAN THERAPEUTICS INC finden Sie auf Wallstreet Online.